5,838 results match your criteria Lymphoma Mantle Cell


Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.

Am J Clin Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family that plays a critical role in the B-cell receptor signaling pathway. It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00535-xDOI Listing

Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.

Int J Hematol 2020 Jul 1. Epub 2020 Jul 1.

Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyusyu University, Fukuoka, Japan.

Duvelisib is a novel dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ. This single-arm, multicenter phase I study investigated its safety, pharmacokinetics, and preliminary efficacy in Japanese patients with relapsed or refractory lymphoma. Duvelisib was administered orally twice daily at 25 mg in 28-day cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02929-3DOI Listing

Histopathological Features and Ann Arbor Stage in Periocular Lymphoma.

In Vivo 2020 Jul-Aug;34(4):1965-1974

Department of Ophthalmology, University Medical Center Rostock, Rostock, Germany

Background: To evaluate biodata, symptoms/signs, lymphoma type, localization, stage level, treatment choice and outcome of ocular adnexal lymphoma (OAL).

Patients And Methods: A single-center retrospective analysis of 56 patients with OAL was performed from 1998 to 2018.

Results: OAL involved the orbit in 44. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.11993DOI Listing

Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T phase IB trial of the LYSA.

Ann Hematol 2020 Jun 29. Epub 2020 Jun 29.

Department of Hematology, CHU de Nantes, University Hospital of Nantes, Nantes, France.

Mantle cell lymphoma has a dismal prognosis at relapse or in the refractory setting. Among therapies, mTor pathway targeting by temsirolimus has been the first strategy approved for relapse in Europe. While its efficacy in monotherapy has long been demonstrated, its use remains limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04159-3DOI Listing

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.

Cancer Res Treat 2020 May 4. Epub 2020 May 4.

Department of Preventative Medicine, Yonsei University College of Medicine, Seoul, Korea.

Purpose: The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea.

Materials And Methods: A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.089DOI Listing

[Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].

Ter Arkh 2019 Jul 15;91(7):41-51. Epub 2019 Jul 15.

National Research Center for Hematology.

Mantle cell lymphoma (MCL) is aggressive B-cell neoplasm diagnosed predominantly among older men. R-CHOP-like regimens allow to achieve high response rate, but the overall survival (OS) are disappointingly short - 3-4 years. An addition of high - dose cytarabine to the upfront therapy and autoSCT significantly improved outcomes but remain feasible largely for medically fit patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000322DOI Listing

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Blood Adv 2020 Jul;4(13):2927-2938

Department of Lymphoma and Myeloma and.

Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect pathogenesis, prognosis, and therapeutic response. In this systematic review, we searched 3 databases and selected 32 articles that described mutations in MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001350DOI Listing

Classification of Digital Pathological Images of Non-Hodgkin's Lymphoma Subtypes Based on the Fusion of Transfer Learning and Principal Component Analysis.

Med Phys 2020 Jun 27. Epub 2020 Jun 27.

School of computer and control engineering, Qiqihar university, Qiqihar, 161006, China.

Purpose: Non-Hodgkin's lymphoma (NHL) is a serious malignant disease. Delayed diagnosis will cause anemia, increased intracranial pressure, organ failure, and even lead to death. The current main trend in this area is to use deep learning (DL) for disease diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14357DOI Listing

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.

Leukemia 2020 Jun 26. Epub 2020 Jun 26.

Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma subtype arising from naïve B cells. Although novel therapeutics have improved patient prognosis, drug resistance remains a key problem. Here, we show that the SRC-family tyrosine kinase hematopoietic cell kinase (HCK), which is primarily expressed in the hematopoietic lineage but not in mature B cells, is aberrantly expressed in MCL, and that high expression of HCK is associated with inferior prognosis of MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0934-6DOI Listing

Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.

Blood 2020 Jun 25. Epub 2020 Jun 25.

Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with two molecular subtypes, conventional (cMCL) and leukemic non-nodal (nnMCL), that differ in their clinicobiological behavior. To identify the genetic/epigenetic alterations determining this diversity, we used whole-genome (n=61) and exome (n=21) sequencing (74% cMCL, 26% nnMCL) combined with transcriptome and DNA methylation profiles in the context of five MCL reference epigenomes. We identified that open and active chromatin at the major translocation cluster locus might facilitate the t(11;14)(q13;32), which modifies the 3-dimensional structure of the involved regions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005289DOI Listing

Lymphoma of the lacrimal gland - An International Multicenter Retrospective Study.

Am J Ophthalmol 2020 Jun 20. Epub 2020 Jun 20.

Eye Pathology Section, Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address:

Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival.

Design: Multi-center retrospective interventional case series.

Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980 through December 31, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2020.06.015DOI Listing

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.

Br J Haematol 2020 Jun 22. Epub 2020 Jun 22.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16902DOI Listing

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.

J Exp Med 2020 Sep;217(9)

Division of Oncology, Stanford University, Stanford, CA.

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20191712DOI Listing
September 2020

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Bone Marrow Transplant 2020 Jun 18. Epub 2020 Jun 18.

Department Medicine V, University of Heidelberg, Heidelberg, Germany.

Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecutive patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and peripheral T-cell lymphoma (PTCL) for whom a donor search was performed between 2004 and 2018. Primary endpoint was overall survival (OS) measured from search initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0976-4DOI Listing
June 2020
3.570 Impact Factor

[Relationship of Expression of Circ_cgga162 with the Prognosis of Patients with Mantle Cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Jun;28(3):876-880

Department of Hematology, The Second Affilated Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China,E-mail:

Objective: To investigate the expression of Circ_cgga162 in serum of mantle cell lymphoma (MCL) patients and analyze its potential as a prognostic biomarker.

Methods: The expression of Circ_cgga162 in 86 cases of mantle cell lymphoma and 50 cases of lymph node reactive hyperplasia (RH) were detected by real-time quantitative polymerase chain reaction (qRT-PCR). The relationship between the expression of Circ_cgga162 and clinicopathological features was analyzed by univariate analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.03.026DOI Listing

Emerging therapies in mantle cell lymphoma.

J Hematol Oncol 2020 Jun 17;13(1):79. Epub 2020 Jun 17.

Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, 43210, USA.

Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin's lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant eligible patients, or less intensive chemotherapy for the less fit (and transplant-ineligible) patients. Patients eventually relapse with a progressive clinical course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00914-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302387PMC
June 2020
4.812 Impact Factor

Management of Drug Resistance in Mantle Cell Lymphoma.

Cancers (Basel) 2020 Jun 12;12(6). Epub 2020 Jun 12.

MICAH team, INSERM U1245, UNICAEN, 14032 Caen CEDEX 5, France.

Mantle cell lymphoma (MCL) is a rare but aggressive B-cell hemopathy characterized by the translocation t(11;14)(q13;q32) that leads to the overexpression of the cell cycle regulatory protein cyclin D1. This translocation is the initial event of the lymphomagenesis, but tumor cells can acquire additional alterations allowing the progression of the disease with a more aggressive phenotype and a tight dependency on microenvironment signaling. To date, the chemotherapeutic-based standard care is largely inefficient and despite the recent advent of different targeted therapies including proteasome inhibitors, immunomodulatory drugs, tyrosine kinase inhibitors, relapses are frequent and are generally related to a dismal prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061565DOI Listing

[Relationship of Expression Between SOX11 and PAX5 in Pathological Tissue Specimens of Patients with Mantle Cell Lymphoma and Its Clinical Significance].

Sichuan Da Xue Xue Bao Yi Xue Ban 2020 May;51(3):355-360

Department of Hematology/Hemaology Research Laboratory, West China Hospital, Sichuan University, Chengdu 610041, China.

Objective: Investigate the expression of SRY-related HMG box 11 (SOX11) and paired box domain 5 (PAX5) in patients with mantle cell lymphoma (MCL) and analyze the relationship between them and their clinical significance.

Methods: Seventy-six formalin-fixed paraffin-embedded (FFPE) samples of patients who were diagnosed with MCL from January 2012 to August 2017 were collected.Fifty-six FFPE samples from patients with diffuse large B cell lymphoma (DLBCL), thirty-eight FFPE samples from patients with follicular lymphoma (FL) and nine FFPE samples from patients with Burkitt's lymphoma (BL) were used as control groups. Real-time quantitative PCR (qRT-PCR) and immunohistochemistry were used to detect the mRNA and protein expressions of SOX11 and PAX5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12182/20200560605DOI Listing

Flow cytometry in the diagnosis of mature B-cell lymphoproliferative disorders.

Int J Lab Hematol 2020 Jun;42 Suppl 1:113-120

Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France.

B-lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre-analytical precautions required for an adequate assessment, the immunophenotypic features of small-cell and large-cell lymphomas are described in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.13170DOI Listing

Hematologist-Level Classification of Mature B-Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data.

Cytometry A 2020 Jun 9. Epub 2020 Jun 9.

MLL Munich Leukemia Laboratory, Munich, Germany.

The wealth of information captured by multiparameter flow cytometry (MFC) can be analyzed by recent methods of computer vision when represented as a single image file. We therefore transformed MFC raw data into a multicolor 2D image by a self-organizing map and classified this representation using a convolutional neural network. By this means, we built an artificial intelligence that is not only able to distinguish diseased from healthy samples, but it can also differentiate seven subtypes of mature B-cell neoplasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.a.24159DOI Listing

QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach.

Drug Deliv Transl Res 2020 Jun 9. Epub 2020 Jun 9.

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India.

Ibrutinib (IBR) is the choice of drug for the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). IBR has low oral bioavailability of 2.9% owing to its high first pass metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13346-020-00803-7DOI Listing

Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan.

Int J Hematol 2020 Jun 9. Epub 2020 Jun 9.

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan S. Rd., Taipei City, 10002, Taiwan.

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma often with extranodal involvement at diagnosis, and yet how this feature correlates with survival awaits elucidation. To address this issue, a correlative analysis between clinical features of 127 MCL patients and their overall survival (OS) was conducted. In this cohort, the median age at MCL diagnosis was 62 years and 81% were males. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02903-zDOI Listing

CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?

Cancer Cell 2020 Jun;37(6):761-763

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

In the New England Journal of Medicine, Wang et al. report favorable ZUMA-2 trial results of CAR T cells for patients with relapsed and refractory mantle cell lymphoma following prior failed Bruton's tyrosine kinase inhibitor therapy, with an overall response rate of 93% and an expected safety profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.05.015DOI Listing

Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.

J Thromb Haemost 2020 Jun 8. Epub 2020 Jun 8.

City Clinical Hospital named after S.P. Botkin, Moscow, Russia.

Background: Therapy with irrevesible Bruton's tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is associated with bleeding.

Objectives: To propose the predictive markers of such bleeding, as well as mechanisms responsible for decreased bleeding at later therapy stages. Patients/Methods We investigate platelet functional activity in 50 CLL and 16 MCL patients on ibrutinib using flow cytometry and light transmission aggregometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14943DOI Listing

Sister Mary Joseph nodule in mantle cell lymphoma.

Lancet Oncol 2020 Jun;21(6):e337

Department of Haematology, Beaumont Hospital, Dublin, Ireland; Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30203-5DOI Listing

Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas.

Mod Pathol 2020 Jun 1. Epub 2020 Jun 1.

Section of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.

The Epstein-Barr virus (EBV) is linked to various B-cell lymphomas, including Burkitt lymphoma (BL), classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) at frequencies ranging, by routine techniques, from 5 to 10% of cases in DLBCL to >95% in endemic BL. Using higher-sensitivity methods, we recently detected EBV traces in a few EBV-negative BL cases, possibly suggesting a "hit-and-run" mechanism. Here, we used routine and higher-sensitivity methods (qPCR and ddPCR for conserved EBV genomic regions and miRNAs on microdissected tumor cells; EBNA1 mRNA In situ detection by RNAscope) to assess EBV infection in a larger lymphoma cohort [19 BL, 34 DLBCL, 44 cHL, 50 follicular lymphomas (FL), 10 T-lymphoblastic lymphomas (T-LL), 20 hairy cell leukemias (HCL), 10 mantle cell lymphomas (MCL)], as well as in several lymphoma cell lines (9 cHL and 6 BL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0575-3DOI Listing

Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.

Cancers (Basel) 2020 May 28;12(6). Epub 2020 May 28.

Department of Hematology, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy.

The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B cell lymphoma, and Waldenstrom's macroglobulinemia. This finding has resulted in the development of numerous drugs that target this pathway, including various inhibitors of the kinases BTK, PI3K, and SYK. Several of these drugs have been approved in recent years for clinical use, resulting in a profound change in the way these diseases are currently being treated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061396DOI Listing

Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.

Ann Diagn Pathol 2020 May 15;46:151534. Epub 2020 May 15.

Department of Pathology, University of California, San Francisco, CA 94143, United States of America. Electronic address:

The diagnosis of a large B-cell lymphoma and classic Hodgkin lymphoma (CHL) is often straightforward. However, in select circumstances, these simple diagnoses can be quite complex. In part, diagnostic difficulty may be due to uncertainty in the evaluation of morphologic and immunophenotypic features along a biologic continuum, or alternatively arise from uncertainty in predicting the behavior and outcomes of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2020.151534DOI Listing

Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.

Hematol Oncol 2020 May 29. Epub 2020 May 29.

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressive conditions rapidly pejorative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2750DOI Listing

Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis.

PLoS Negl Trop Dis 2020 May 29;14(5):e0008336. Epub 2020 May 29.

Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Chikungunya virus (CHIKV) is an alphavirus that causes a febrile illness accompanied by myalgia and arthralgia. Despite having re-emerged as a significant public health threat, there are no approved therapeutics or prophylactics for CHIKV infection. In this study, we explored the anti-CHIKV effects of proteasome inhibitors and their potential mechanism of antiviral action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0008336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286522PMC

Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.

Clin Cancer Res 2020 May 27. Epub 2020 May 27.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China.

Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse is poor, and treatment choices are limited. We evaluated the efficacy and safety of zanubrutinib, an investigational selective Bruton's tyrosine kinase (BTK) inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3703DOI Listing

FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings.

Clin Nucl Med 2020 Jul;45(7):e305-e306

From the Departments of Nuclear Medicine.

A 52-year-old woman with no medical history was admitted on March 18, 2020, presenting since 3 days asthenia, abdominal pain, and dry cough but no fever. Adenomegalies, splenomegaly, leukocytosis, and elevated LDH suggested mature lymphoproliferation. Considering the current health context, an RT-PCR testing for COVID-19 (coronavirus disease 2019) was performed and found to be positive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268867PMC

SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma.

Leuk Lymphoma 2020 May 23:1-14. Epub 2020 May 23.

Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.

SOX11 is a critical biomarker for mantle cell lymphoma (MCL) diagnosis; however, its role remains unclear in MCL. Here, clinical-pathological analysis showed Ki67 index was negatively relevant to SOX11 expression only in CD43 positive cases. Coexpression of SOX11/CD43 indicated longer overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1762877DOI Listing

The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.

Br J Haematol 2020 May 23. Epub 2020 May 23.

Plymouth University Hospitals NHS Trust, Plymouth, UK.

This is a 5-year real-world study of 65 patients treated with ibrutinib for relapsed/refractory mantle cell lymphoma across the UK and Ireland. Ibrutinib was well tolerated with no fatal adverse events. The median progression-free survival and overall survival (OS) was 12 and 18·5 months, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16739DOI Listing

Circular RNA hsa_circ_0008285 inhibits colorectal cancer cell proliferation and migration via the miR-382-5p/PTEN axis.

Biochem Biophys Res Commun 2020 Jun 15;527(2):503-510. Epub 2020 May 15.

Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. Electronic address:

Abundant evidence has showed that circular RNA (circRNA) plays an important role in cancer. Nonetheless, little is known about the roles and mechanisms of specific circRNAs in different cancer types. Hsa_circ_0008285 (circ_0008285), derived from the coding gene chromodomain y-like protein (CDYL), is upregulated in hepatocellular carcinoma and mantle cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2020.03.165DOI Listing

Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2020 May 15. Epub 2020 May 15.

Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.

Although CD19-directed chimeric antigen receptor (CAR) T cells have been successfully used after a preceding allogeneic stem cell transplant (alloHCT) in patients with acute lymphoblastic leukemia, little is known about the feasibility and outcome of CAR T cell treatment in patients who have been previously allotransplanted for lymphoma. In a single-center retrospective analysis, course and outcome of all allografted patients treated with CD19 CAR constructs for B cell lymphoma between October 2018 and November 2019 were studied. CAR therapy consisted either of a third-generation CAR (HD-CAR-1) or of commercially manufactured axicabtagene ciloleucel (axi-cel; Gilead, Santa Monica, U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.025DOI Listing
May 2020
3.404 Impact Factor

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.

Am Soc Clin Oncol Educ Book 2020 May;40:302-313

University of Chicago, Chicago, IL.

Novel immunotherapies and small molecular inhibitors are transforming our approach to previously treated and newly diagnosed patients across the spectrum of non-Hodgkin lymphomas (NHLs). Anti-CD19 CAR T cells are now indicated for the treatment of relapsed/refractory aggressive B-cell lymphomas after at least two previous lines of therapy in which durable remissions are achieved in approximately 40% of previously incurable patients. Second-line chemoimmunotherapy remains the standard of care at first relapse, but poor outcomes with conventional treatment in this setting creates an appealing rationale for earlier use of CAR T cells, which is currently under investigation, along with even earlier use in selected high-risk patients in the frontline setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_279043DOI Listing

Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Cancer Med 2020 May 18. Epub 2020 May 18.

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non-Hodgkin lymphoma. In this study, serine-227 (RSK2 ) in the N-terminal kinase domain (NTKD) of RSK2 was found to be ubiquitously active in five MCL-derived cell lines and in tumor tissues derived from five MCL patients. BI-D1870, an inhibitor specific to RSK2-NTKD, caused RSK2 dephosphorylation, and thereby, induced dose-dependent growth inhibition via G /M cell cycle blockade and apoptosis in four of the five cell lines, while one cell line showed only modest sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3136DOI Listing

Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.

Br J Haematol 2020 May 14. Epub 2020 May 14.

CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy.

Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R-CVAD) alternating with high-dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow-up of 10·5 years, we reported 10-year progression-free and overall survival rates of 35% and 61% respectively, with a 10-years cumulative incidence rate of second malignancies of 10·6%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16714DOI Listing

Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing.

Ann Diagn Pathol 2020 May 6;46:151533. Epub 2020 May 6.

Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:

The accurate detection of recurrent genetic abnormalities for most hematologic neoplasms is critical for diagnosis, prognosis and/or treatment. Rearrangements involving CCND1 are observed in a subset of mature B-cell neoplasms and can be reliably detected by fluorescence in situ hybridization (FISH) in most cases. However, cryptic and complex chromosomal rearrangements may pose a technical challenge for accurate diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2020.151533DOI Listing

Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B.

BMJ Case Rep 2020 May 12;13(5). Epub 2020 May 12.

Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham, UK

Critically ill patients are at risk of developing both acute kidney injury (AKI) and invasive fungal infections (IFIs). Prompt and efficient treatment of the IFI is essential for the survival of the patient. This article examines three distinct clinical situations where liposomal amphotericin B, a broad-spectrum antifungal agent, was successfully used in the setting of AKI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-233072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228453PMC

Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.

Cell Chem Biol 2020 Jun 7;27(6):678-697.e13. Epub 2020 May 7.

University of Parma, Department of Medicine and Surgery, Parma 43126, Italy. Electronic address:

The identification of SERCA (sarco/endoplasmic reticulum calcium ATPase) as a target for modulating gain-of-function NOTCH1 mutations in Notch-dependent cancers has spurred the development of this compound class for cancer therapeutics. Despite the innate toxicity challenge associated with SERCA inhibition, we identified CAD204520, a small molecule with better drug-like properties and reduced off-target Ca toxicity compared with the SERCA inhibitor thapsigargin. In this work, we describe the properties and complex structure of CAD204520 and show that CAD204520 preferentially targets mutated over wild-type NOTCH1 proteins in T cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2020.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305996PMC

Strongyloides stercoralis hyperinfection syndrome in mantle cell lymphoma in post-transplant setting.

Ann Hematol 2020 May 6. Epub 2020 May 6.

Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts, 01655, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04049-8DOI Listing

Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.

Cancers (Basel) 2020 May 2;12(5). Epub 2020 May 2.

Department of Laboratory Medicine, Division of Biomedical and Cellular Medicine, Karolinska Institutet, 141 57 Stockholm, Sweden.

Interactions between lymphoma cells and stromal cells play a key role in promoting tumor survival and development of drug resistance. We identified differences in key signaling pathways between the JeKo-1 and REC-1 mantle cell lymphoma (MCL) cell lines, displaying different patterns of stromal cell adhesion and chemotaxis towards stroma-conditioned medium. The identified adhesion-regulated genes reciprocated important aspects of microenvironment-mediated gene modulation in MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281289PMC

[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients.

Cancers (Basel) 2020 May 2;12(5). Epub 2020 May 2.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Biopsy is the standard for assessment of bone marrow involvement in mantle cell lymphoma (MCL). We investigated whether [18F]FDG-PET radiomic texture features can improve prediction of bone marrow involvement in MCL, compared to standardized uptake values (SUV), and whether combination with laboratory data improves results. Ninety-seven MCL patients were retrospectively included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281173PMC

Primary cutaneous mantle cell lymphoma: Report of a rare case.

World J Clin Cases 2020 Apr;8(8):1507-1514

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Background: We describe the case of a 74-year-old man diagnosed with primary cutaneous mantle cell lymphoma (MCL), an extremely rare and controversial condition that is not included in the World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas.

Case Summary: The patient presented diffuse cutaneous erythematous plaques and nodules throughout the body. Skin lesions were biopsied and histopathological examination showed diffuse monomorphic lymphocyte infiltration in the dermal and subcutaneous layers, sparing the epidermis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i8.1507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190952PMC